Company: ARTL
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001640334-25-000825
Chunk: 132

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 132
---
holders. 

 18Table of Contents

Product Candidate Pipeline:

Product CandidateTarget Indication(s)Development PhaseEstimated Global Market SizeART27.13 – Synthetic Dual Cannabinoid GPCR AgonistCancer-related anorexiaClinicalCancer anorexia cachexia syndrome: >$3 billionART26.12 – FABP5 inhibitorCIPN, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disordersClinicalCIPN: >$2 billionProstate cancer: approximately $13 billionBreast cancer: approximately $33 billionPsoriasis: $31 billionPTSD: approximately $13 billionART12.11 – Synthetic CBD CocrystalAnxiety, depression, PTSD, and other potential indicationsPre-clinicalAnxiety disorders: >$13 billionPTSD: approximately $13 billion

Background

Emerging science suggests that modulating lipid-signaling pathways can unlock novel therapeutic strategies for diseases and medical conditions for which there are no or limited options. Lipids are critical to certain cell signaling pathways. Lipid-signaling modulation is the alteration of the signaling of lipid molecules to change biological activity or function within cellular communication pathways. Lipids contain various fatty acids as their building blocks and are the key components of lipid activity. Fatty Acid Binding Proteins (FABPs) facilitate lipid-signaling by binding to fatty acids which control various cellular functions. FABPs are essential mediators of normal cell signaling processes and under certain conditions can be associated with dysfunctional signaling. Inhibition of specific FABPs may correct abnormal lipid-signaling or improve the function of the ECS, which holds promise as new treatment modalities. We are at the forefront of advancing the application of lipid-modulating therapeutics.

The ECS is composed of cannabinoid receptors, endogenous receptor ligands (“endocannabinoids”) and their associated transporter mechanisms, as well as enzymes responsible for the synthesis and degradation of endocannabinoids and has emerged as a considerable target for pharmacotherapy approaches of numerous human diseases. As a widespread modulatory and lipid-signaling system, the ECS plays important roles in the CNS, development, synaptic plasticity, and the response to endogenous and environmental factors.

The modulation of the ECS can be affected by using selective or non-selective agonists, partial agonists, inverse agonists, and antagonists of the cannabinoid receptors, CB1 and CB2. The CB1 receptor is distributed in brain areas associated with motor control, emotional responses, motivated behavior and energy homeostasis. In